Baseline characteristics of patients
| Characteristic . | 1° AML, no. (%) . | 2° AML, no. (%) . | tAML, no. (%) . |
|---|---|---|---|
| Sample size (N = 114) | 78 (68) | 19 (17) | 17 (15) |
| Age, y | |||
| Median | 59 | 71 | 61 |
| Range | 20-80 | 50-85 | 24-73 |
| Sex | |||
| Male | 49 (63) | 12 (63) | 5 (29) |
| Female | 29 (37) | 7 (37) | 12 (71) |
| FAB classification* | |||
| M0 | 11 (14) | 2 (11) | 1 (6) |
| M1 | 10 (13) | 0 (0) | 3 (18) |
| M2 | 12 (15) | 4 (21) | 2 (12) |
| M3 | 0 (0) | 0 (0) | 0 (0) |
| M4 | 29 (37) | 5 (26) | 4 (24) |
| M5 | 8 (10) | 1 (5) | 2 (12) |
| M6 | 0 (0) | 0 (0) | 0 (0) |
| M7 | 0 (0) | 0 (0) | 0 (0) |
| Cytogenetic class | |||
| Favorable | 8 (10) | 0 (0) | 0 (0) |
| Intermediate | 44 (57) | 10 (53) | 6 (35) |
| Unfavorable | 26 (33) | 9 (47) | 11 (65) |
| Complex karyotype | |||
| Yes | 12 (15) | 6 (32) | 8 (47) |
| No | 66 (85) | 13 (68) | 9 (53) |
| 5q−/−5 cytogenetics status | |||
| Present | 10 (13) | 2 (11) | 8 (47) |
| Absent | 68 (87) | 17 (89) | 9 (53) |
| 7q−/−7 cytogenetics status | |||
| Present | 10 (13) | 4 (21) | 6 (35) |
| Absent | 68 (87) | 15 (79) | 11 (65) |
| NPM1 exon 12 status† | |||
| Mutated | 15 (19) | 1 (5) | 2 (12) |
| Wild-type | 63 (81) | 17 (89) | 15 (88) |
| p53 exons 2-9 status† | |||
| Mutated | 8 (10) | 3 (16) | 7 (41) |
| Wild-type | 69 (90) | 15 (79) | 10 (59) |
| FLT3 ITD status† | |||
| ITD present | 11 (14) | 0 (0) | 3 (18) |
| Wild-type | 67 (86) | 18 (100) | 14 (82) |
| Characteristic . | 1° AML, no. (%) . | 2° AML, no. (%) . | tAML, no. (%) . |
|---|---|---|---|
| Sample size (N = 114) | 78 (68) | 19 (17) | 17 (15) |
| Age, y | |||
| Median | 59 | 71 | 61 |
| Range | 20-80 | 50-85 | 24-73 |
| Sex | |||
| Male | 49 (63) | 12 (63) | 5 (29) |
| Female | 29 (37) | 7 (37) | 12 (71) |
| FAB classification* | |||
| M0 | 11 (14) | 2 (11) | 1 (6) |
| M1 | 10 (13) | 0 (0) | 3 (18) |
| M2 | 12 (15) | 4 (21) | 2 (12) |
| M3 | 0 (0) | 0 (0) | 0 (0) |
| M4 | 29 (37) | 5 (26) | 4 (24) |
| M5 | 8 (10) | 1 (5) | 2 (12) |
| M6 | 0 (0) | 0 (0) | 0 (0) |
| M7 | 0 (0) | 0 (0) | 0 (0) |
| Cytogenetic class | |||
| Favorable | 8 (10) | 0 (0) | 0 (0) |
| Intermediate | 44 (57) | 10 (53) | 6 (35) |
| Unfavorable | 26 (33) | 9 (47) | 11 (65) |
| Complex karyotype | |||
| Yes | 12 (15) | 6 (32) | 8 (47) |
| No | 66 (85) | 13 (68) | 9 (53) |
| 5q−/−5 cytogenetics status | |||
| Present | 10 (13) | 2 (11) | 8 (47) |
| Absent | 68 (87) | 17 (89) | 9 (53) |
| 7q−/−7 cytogenetics status | |||
| Present | 10 (13) | 4 (21) | 6 (35) |
| Absent | 68 (87) | 15 (79) | 11 (65) |
| NPM1 exon 12 status† | |||
| Mutated | 15 (19) | 1 (5) | 2 (12) |
| Wild-type | 63 (81) | 17 (89) | 15 (88) |
| p53 exons 2-9 status† | |||
| Mutated | 8 (10) | 3 (16) | 7 (41) |
| Wild-type | 69 (90) | 15 (79) | 10 (59) |
| FLT3 ITD status† | |||
| ITD present | 11 (14) | 0 (0) | 3 (18) |
| Wild-type | 67 (86) | 18 (100) | 14 (82) |
1° AML indicates de novo AML; 2° AML, AML with antecedent myelodysplasia or MPD; tAML, treatment-related AML; and ITD, internal tandem duplication.
The French-American-British (FAB) classification was unspecified in 20 samples.
Data are unavailable for NPM1 in 1 case, p53 in 2 cases, and FLT3 in 1 case.